Tagraxofusp

Tagraxofusp (Elzonris, Stemline Therapeutics B.V.) has 1 EU-approved indication in 1 tumour type.
Approved indications of Tagraxofusp
Biomarker requirementRegimenSettingConditions
Blastic plasmacytoid dendritic cell neoplasm1
None
Monotherapy
1L
None
Full text of section 4.1 (therapeutic indications)

ELZONRIS is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) (see section 5.1).

Label history

8 changes to the Elzonris label since 2022, none of them to the indications. Newest first, in the words of EMA's record of each procedure.

Changes